Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR by Ha, Sang Yun et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most
often involving EGFR
Ha, Sang Yun; Choi, So-Jung; Cho, Jong Ho; Choi, Hye Joo; Lee, Jinseon; Jung, Kyungsoo;
Irwin, Darry; Liu, Xiaoli; Lira, Maruja E.; Mao, Mao; Kim, Hong Kwan; Choi, Yong Soo; Shim,
Young Mog; Park, Woong Yang; Choi, Yoon-La; Kim, Jhingook
Published in:
OncoTarget
DOI:
10.18632/oncotarget.2925
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Ha, S. Y., Choi, S-J., Cho, J. H., Choi, H. J., Lee, J., Jung, K., ... Kim, J. (2015). Lung cancer in never-smoker
Asian females is driven by oncogenic mutations, most often involving EGFR. OncoTarget, 6(7), 5465-5474.
https://doi.org/10.18632/oncotarget.2925
Download date: 03. Feb. 2020
Oncotarget5465www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No.7
Lung cancer in never-smoker Asian females is driven by 
oncogenic mutations, most often involving EGFR
Sang Yun Ha1,*, So-Jung Choi2,*, Jong Ho Cho3,*, Hye Joo Choi2, Jinseon Lee2, 
Kyungsoo Jung4, Darry Irwin5, Xiao Liu6,7, Maruja E. Lira8, Mao Mao9, Hong Kwan
Kim3, Yong Soo Choi3, Young Mog Shim3, Woong Yang Park10, Yoon-La Choi1,4,10, 
Jhingook Kim2,3
1 Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea
2 Samsung Biomedical Research Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 
Korea
3 Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Samsung Biomedical Research Institute, 
Sungkyunkwan University School of Medicine, Seoul, Korea
4Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University School of Medicine, Seoul, Korea
5Agena Bioscience, Sequenom, San Diego, CA, USA
6BGI-Shenzhen, Shenzhen, 518083, China
7Department of Biology, University of Copenhagen, Copenhagen, Denmark
8Oncoloy Research Unit, Pfizer Worldwide Research and Development, San Diego, CA, USA
9WuXi AppTec, Shanghai, China
10Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
*These authors contributed equally to this work
Correspondence to:
Jhingook Kim, e-mail: jhingookkim@gmail.com
Yoon-La Choi, e-mail: ylachoi@skku.edu
Keywords: non-small cell lung cancer, adenocarcinoma, never-smoker female, driver mutation, EGFR
Received: August 07, 2014 Accepted: December 16, 2014 Published: February 28, 2015
ABSTRACT
The aim of this study was to determine the distribution of known oncogenic 
driver mutations in female never-smoker Asian patients with lung adenocarcinoma. 
We analyzed 214 mutations across 26 lung cancer-associated genes and three fusion 
genes using the MassARRAY® LungCarta Panel and the ALK, ROS1, and RET fusion 
assays in 198 consecutively resected lung adenocarcinomas from never-smoker 
females at a single institution. EGFR mutation, which was the most frequent driver 
gene mutation, was detected in 124 (63%) cases. Mutation of ALK, KRAS, PIK3CA, 
ERBB2, BRAF, ROS1, and RET genesoccurred in 7%, 4%, 2.5%, 1.5%, 1%, 1%, and 
1% of cases, respectively. Thus, 79% of lung adenocarcinomas from never-smoker 
females harbored well-known oncogenic mutations. Mucinous adenocarcinomas 
tended to have a lower frequency of known driver gene mutations than other 
histologic subtypes. EGFR mutation was associated with older age and a predominantly 
acinar pattern, while ALK rearrangement was associated with younger age and a 
predominantly solid pattern. Lung cancer in never-smoker Asian females is a distinct 
entity, with the majority of these cancers developing from oncogenic mutations.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
mortality, with 1.38 million annual deaths worldwide 
[1]. Tobacco smoking is the main risk factor for lung 
cancer; however, approximately 25% of lung cancers 
worldwide occur in never-smokers [2, 3]. Moreover, 
the risk of lung cancer differs by race/ethnicity. In the 
United States, approximately 10% of patients with lung 
cancer are never-smokers [4], while in Asia, >30% of 
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patients with lung cancer are never-smokers and ≥50% 
of lung cancers occur in women who are never-smokers 
[5]. Never-smoker East Asian females have a tendency to 
develop adenocarcinoma, and these never-smokers exhibit 
higher treatment response rates to epidermal growth factor 
receptor tyrosine kinase inhibitors (EGFR-TKIs), such as 
gefitinib and erlotinib, than those with a history of tobacco 
smoking [6]. In several phase III studies, significantly 
better response rates and longer progression-free survival 
were observed in advanced non-small cell lung cancer 
(NSCLC) patients harboring activating EGFR mutations 
who were treated with first-line EGFR-TKIs than those 
patients treated with doublet platinum-based chemotherapy 
[7, 8]. In addition, a fusion protein of the N-terminal 
portion of the echinoderm microtubule-associated 
protein-like 4 (EML4) gene and the intracellular signaling 
portion of the anaplastic lymphoma kinase (ALK) tyrosine 
kinase receptor has been identified in a small subset of 
NSCLC patients [9]. Patients harboring the EML4-ALK 
fusion show unique clinicopathologic and physiological 
characteristics and respond positively to ALK inhibitors 
[10–12]. As for EGFR mutations, several reports have 
identified the EML4-ALK fusion protein predominantly 
in young female never-smokers with adenocarcinoma, 
although the presence of this fusion protein is mutually 
exclusive with EGFR mutation [9, 13]. More specifically, 
the EML4-ALK fusion gene was found in 23.7% of never-
smoker female lung adenocarcinoma patients [14].
Lung adenocarcinoma in never-smoker females has 
been established as a distinct entity based on its particular 
epidemiologic, clinical, and biological characteristics. 
EGFR mutations and the EML4-ALK translocation are 
defined as driver mutations because these alterations are 
responsible for both initiation and maintenance of lung 
cancer. The discovery of driver oncogene genetic variants 
that are sensitive to molecular-targeted drugs is crucial 
for improvement of treatment strategies. Therefore, use 
of multi-mutational profiling in lung cancer studies is 
important for identification of driver gene alterations in 
order to validate the effectiveness of molecular-targeted 
therapies. In addition, the proportion of never-smokers 
with lung cancer is likely to increase as a result of smoking 
cessation and prevention programs. Thus, the aims of 
this study were to analyze the distribution of oncogenic 
driver mutations and to compare these mutations with 
clinicopathologic characteristics in female Asian never-
smoker lung adenocarcinoma patients.
RESULTS
Patient population and histopathologic 
classification
The patient population is summarized in Table 1. All 
patients were women with no smoking history. Median 
age at diagnosis was 60 years (range, 29–81 years). Most 
patients (85.3%) had undergone lobectomy. Two patients 
had pleural metastasis at the time of surgery. Eleven 
(5.6%) patients had received neoadjuvant concurrent 
chemoradiation therapy. Among the 198 patients in this 
study, 104 (52.5%) patients had T1 stage tumors, 83 
(41.9%) patients had T2 stage tumors, and 11 (5.6%) 
patients had T3 stage tumors. Nine patients did not 
undergo lymph node dissection and were excluded from 
the analysis of N stage. N0, N1, and N2 stage tumors were 
observed in 124 (65.6%), 25 (13.2%), and 40 (21.2%) 
patients, respectively. Two of the 198 cases were classified 
as minimally invasive adenocarcinomas with an invasive 
component of <5 mm. Invasive adenocarcinomas were 
classified as predominantly acinar (142 cases, 71.7%), 
predominantly papillary (18 cases, 9.1%), predominantly 
solid (17 cases, 8.6%), predominantly lepidic (9 cases, 
4.5%), and predominantly micropapillary (1 case, 
0.5%) patterns. Nine (4.5%) cases were classified as 
mucinous adenocarcinoma. Two minimally invasive 
adenocarcinomas were classified as predominantly 
lepidic for statistical analysis. In addition, all histologic 
patterns that were observed in >10% of the tumor area 
were recorded. An acinar pattern was observed in 169 
(85.4%) cases. Papillary, lepidic, micropapillary, solid, 
and mucinous patterns were observed in 68 (34.3%), 36 
(18.2%), 36 (18.2%), 33 (16.7%), and 17 (8.6%) cases, 
respectively.
Fusion gene and LungCarta analyses
The results of the fusion gene and LungCarta 
analyses are summarized in Figure 2 and Table 2, and 
a full list of mutations that were identified is shown 
in Supplemental Table 1. Among the 198 cases, driver 
mutations were detected in 157 (79%) cases. EGFR 
mutations were the most frequently found mutation in 
lung adenocarcinomas of female never-smokers (124 
cases, 63%). EGFR mutations were detected in exon 
19 in 47 (24%) cases, exon 20 in 16 (8%) cases, exon 
21 in 58 (29%) cases, exons 18 and 21 in 2 (1%) cases, 
and exons 18 and 20 in 1 (1%) case. ALK rearrangement 
was observed in 14 (7%) of cases. The frequencies of 
KRAS, PIK3CA, TP53, ERBB2, and BRAF mutations 
were 4%, 2.5%, 2%, 1.5%, and 1%, respectively. ROS1 
and RET gene rearrangements were each found in 2 
(1%) cases. ALK, ROS1, and RET gene fusions were 
mutually exclusive with EGFR and KRAS mutations. 
The gene mutations were mutually exclusive with the 
exception of concurrent mutation of EGFR/PIK3CA 
(n = 3), EGFR/TP53 (n = 1), ALK/TP53 (n = 2), 
KRAS/PIK3CA (n = 1), and KRAS/ERBB2 (n = 1; 
Figure 3). The results of Sanger sequencing validation 
were consistent with the results of LungCarta analyses 
in all cases (Supplemental Table 2).
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Relationship between driver mutation status and 
clinicopathologic characteristics
The relationship between the driver mutation 
status and histologic subclassification of adenocarcinoma 
is summarized in Table 2 and Figure 4A–4E. Tumors 
with EGFR mutation exhibited a high frequency of 
predominantly acinar patterns and an absence of a 
predominantly mucinous pattern. ALK rearrangements 
were frequently found in cases with a predominantly solid 
pattern. KRAS mutations were detected with high frequency 
in cases with predominantly mucinous tumors. BRAF 
mutations were detected only in predominantly papillary 
tumors. These four genes were significantly associated with 
the histologic subclassification. Mucinous adenocarcinoma 
tended to harbor a lower frequency of known driver gene 
mutations than other histologic subtypes (mutation rate, 
44.4% vs. 80.4%; p = 0.090).
Table 1: Patient population
Characteristics Number of patients (%)
Age, years median 60 (range, 29–81)
Histologic classification
  Minimally invasive adenocarcinoma 2 (1.0)
  Invasive adenocarcinoma
   Lepidic predominant 9 (4.5)
   Acinar predominant 142 (71.7)
   Papillary predominant 18 (9.1)
   Micropapillary predominant 1 (0.5)
   Solid predominant 17 (8.6)
  Mucinous adenocarcinoma 9 (4.5)
T stage
  1 104 (52.5)
  2 83 (41.9)
  3 11 (5.6)
N stage1
  0 124 (65.6)
  1 25 (13.2)
  2 40 (21.2)
M stage
  0 196 (99.0)
  1 2 (1.0)
Operation
  Wedge resection 16 (8.0)
  Lobectomy 169 (85.3)
  Lobectomy + α2 13 (6.6)
Neoadjuvant CCRT3
  Yes 11 (5.6)
  No 187 (94.4)
1Nine cases were excluded because lymph node dissection was not performed.
2α includes lobectomy with wedge resection of the other lobe, bilobectomy, or pneumonectomy.
3CCRT indicates concurrent chemoradiation therapy.
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EGFR mutations were associated frequently with 
lepidic and acinar patterns and infrequently with mucinous 
patterns in cases where the histologic pattern predominated 
in >10% of the tumor area. ALK rearrangement was more 
frequently detected in tumors with solid and mucinous 
patterns, while KRAS mutations were also commonly 
found in tumors with a mucinous pattern. Other 
mutations were not associated with histologic subtypes 
(Supplemental Table 3).
Patients with tumors harboring EGFR and BRAF 
mutations were older than those with wild-type tumors, 
whereas ALK gene fusions and ERBB2 mutations were 
Figure 2: Frequency of driver gene mutations in lung adenocarcinomas from East Asian never-smoker females.
Figure 1: Process of patient (female never smoker with lung adenocarcinoma) selection in this study. (A) Distribution 
of lung cancer according to histology subtype. (B) Distribution of lung adenocarcinoma according to gender. (C) Distribution of lung 
adenocarcinoma from female according to smoking status. Patients with no medical record of smoking status were excluded. The record of 
year 2012 was not shown due to lack of smoking information.
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associated with younger age at diagnosis (Supplemental 
Table 4). Driver gene mutation status was not associated 
with tumor stage.
DISCUSSION
In this study, we evaluated the status of driver gene 
mutations in lung adenocarcinoma samples from 198 East 
Asian female never-smokers using the MassARRAY® 
LungCarta Panel and ALK, ROS1, and RET fusion 
assays. Approximately 79% of patients harbored driver 
gene mutations, and EGFR mutation (63%) was the 
most frequent driver mutation detected. Other genetic 
alterations occurred less frequently with ALK gene fusion, 
KRAS mutation, ERBB2 mutation, HER2 mutation, ROS1 
rearrangement, and RET rearrangement occurring in 7%, 
Figure 3: Diagram demonstrating driver gene mutation status and clinicopathologic features in 198 adenocarcinomas 
from East Asian never-smoker females. Most mutations were mutually exclusive with the rare exception of concurrent mutation of 
EGFR/PIK3CA (n = 3), EGFR/TP53 (n = 1), ALK/TP53 (n = 2), KRAS/PIK3CA (n = 1), and KRAS/ERBB2 (n = 1). Patients who received 
concurrent chemoradiation therapy and those who did not undergo lymph node dissection were excluded in the analysis of TNM stage.
Table 2: Relationship between driver mutation status and histologic subclassification of 
adenocarcinoma according to predominant type
Total Lepidic1 Acinar2 Papillary Micropapillary Solid Mucinous3 p-value
n (%) 198 (100) 11 (5.6) 142 (71.7) 18 (9.1) 1 (0.5) 17 (8.6) 9 (4.5)
Wild-type 41 (20.7) 3 (7.3) 29 (70.7) 2 (4.9) 0 (0) 3 (7.3) 4 (9.8)
0.446 
Mucinous 
vs. others: 
0.090
Mutant type 157 (79.3) 8 (5.1) 113 (72.0) 16 (10.2) 1 (0.6) 14 (8.9) 5 (3.2)
EGFR 124 (62.6) 7 (5.6) 102 (82.3) 9 (7.3) 1 (0.8) 5 (4.0) 0 (0) <0.001
ALK 14 (7.1) 0 (0) 6 (42.9) 2 (14.3) 0 (0) 5 (35.7) 1 (7.1) 0.012
KRAS 8 (4.0) 1 (12.5) 1 (12.5) 0 (0) 0 (0) 2 (25.0) 4 (50.0) <0.001
PIK3CA 5 (2.5) 0 (0) 3 (60.0) 1 (20.0) 0 (0) 0 (0) 1 (20.0) 0.31
TP53 4 (2.0) 0 (0) 4 (2.8) 0 (0) 0 (0) 0 (0) 0 (0) 1
ERBB2 3 (1.5) 0 (0) 2 (66.7) 0 (0) 0 (0) 0 (0) 1 (33.3) 0.272
BRAF 2 (1.0) 0 (0) 0 (0) 2 (100) 0 (0) 0 (0) 0 (0) 0.043
ROS1 2 (1.0) 0 (0) 0 (0) 1 (50.0) 0 (0) 1 (50.0) 0 (0) 0.086
RET 2 (1.0) 0 (0) 1 (50.0) 1 (50.0) 0 (0) 0 (0) 0 (0) 0.487
NRAS 1 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 0.192
1Two cases of minimally invasive adenocarcinoma were included in the lepidic predominant type.
2Six cases with acinar pattern showed concurrent mutation of EGFR/PIK3CA (n = 3), EGFR/TP53 (n = 1), and ALK/TP53 (n = 2).
3Two cases of mucinous adenocarcinoma showed concurrent mutation of KRAS/PIK3CA (n = 1) and KRAS/ERBB2 (n = 1).
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Figure 4: Frequency of driver gene mutations according to predominant histologic subtype. (A) Lepidic, (B) Acinar, 
(C) Papillary, (D) Solid, (E) Mucinous subtype. In acinar subtype, four cases with concurrent mutations of EGFR/PIK3CA (n = 3) and 
EGFR/TP53 (n = 1) are represented as an EGFR mutation, and 2 cases of ALK/TP53 mutation as an ALK mutation. In mucinous subtype, 
two cases with concurrent mutations of KRAS/PIK3CA and KRAS/ERBB2 are represented as a KRAS mutation.
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4%, 1.5%, 1%, 1%, and 1% of cases, respectively. Most 
mutations were mutually exclusive.
Ethnic background is a well-established factor in 
NSCLC. Asian female non-smokers were the specific 
epidemiologic subgroup in this study, and a few previous 
large-scale studies have shown that Asian ethnicity is a 
prognostic factor of overall survival for NSCLC patients 
[15–17]. The link between ethnicity and cancer survival 
rates is likely due to differences in genetic background 
among ethnicities. Compared to Caucasians, East Asians 
with NSCLC have higher rates of EGFR mutations 
and lower rates of KRAS and LKB1 mutations [18]. 
According to a recent meta-analysis of 94 studies, the 
rate of EGFR mutation in lung adenocarcinoma in Asians 
(47.9%) is higher than that in Westerners (19.2%), while 
KRAS (11.2%) and LKB1 (4.0%) mutation rates are 
lower in Asians than in Westerners (26.1% and 16.2%, 
respectively) [19]. Smoking status is also an important 
factor in the development of lung adenocarcinoma. Lung 
cancers in never-smokers are more frequently associated 
with adenocarcinoma with EGFR mutations and less 
frequently with KRAS mutations [20]. In a recent study of 
lung adenocarcinomas, mutation rates for EGFR (39%), 
KRAS (4%), ALK (15%), and HER2 (5%) in never-smoker 
groups differed from rates in current or former smoker 
groups (10%, 35%, 4%, and 1%, respectively) [21]. 
Notably, the proportion of female lung cancers in never-
smokers is much higher in East Asia than in Europe or the 
United States (60% vs 15–20%) [20].
Although many studies have investigated driver 
gene mutations in lung adenocarcinoma, only a few have 
focused specifically on Asian female never-smokers 
despite the demonstrated importance of this patient group 
for selection of targeted candidates for NSCLC therapy 
[22–24]. Zhang et al. analyzed EGFR, KRAS, ALK, HER2, 
and BRAF mutation in 349 Chinese never-smoker females 
with lung adenocarcinoma and discovered mutation rates 
of 76%, 5%, 4%, 2%, and 1% for EGFR, HER2, ALK, 
KRAS, and HER2, respectively, while only 12% of cases 
harbored no detected mutation [25]. In an analysis of 
mutations of 10 driver genes (EGFR, KRAS, NRAS, 
HRAS, HER2, BRAF, ALK, PIK3CA, TP53, and LKB1) in 
52 lung adenocarcinomas from East Asian never-smokers 
including 41 women [26], Sun et al. found similar rates 
of genetic alterations: EGFR mutation in 79% of cases, 
EML4-ALK fusion in 6% of cases, HER2 mutation in 4% 
of cases, and KRAS mutation in 2% of cases. In addition, 
only 10% of patients did not harbor any detected mutation 
in these genes. Ren et al. reported EGFR mutation in 70% 
and ALK rearrangement in 9.6% in adenocarcinomas from 
never-smoker Chinese women (see Supplemental Table 5 
for summary of these studies) [27]. The incidences of 
mutation detected in this study are consistent with those 
of previous studies.
Several important features distinguish our study 
from previous studies. In our study, we analyzed a total of 
26 known oncogenes and 3 fusion genes. We discovered 
that 1% of lung adenocarcinomas from East Asian never-
smoker female patients harbored gene rearrangements of 
ROS1 and RET, which have recently been recognized as 
driver genes in lung adenocarcinoma [28–30] but had not 
been evaluated in East Asian female never-smokers. We 
used a multiplex method that can be used in routine clinical 
practice and our results demonstrated that this method 
was comparable to traditional mutational analysis using 
polymerase chain reaction (PCR) for each gene. The use 
of a multiplexed PCR-based assay to genotype NSCLCs 
was recently demonstrated to be clinically feasible [31]. 
Moreover, we confirmed well-known associations of 
driver gene mutations with histologic subtypes and clinical 
characteristics. EGFR mutation correlated positively with 
older age and a predominantly acinar pattern [25, 32, 33], 
while ALK rearrangement was associated with younger 
age and solid histology [34, 35]. KRAS mutation was 
detected more frequently in mucinous adenocarcinoma 
[25, 36]. Furthermore, most PIK3CA mutations coexisted 
with other mutations [26]. The fact that our findings are 
consistent with those of previous studies supports the 
value of the multiplex method in mutation analysis and 
suggests that clinicopathologic associations are useful for 
determination of the priority of driver mutation tests.
The most outstanding result of our study was that 
driver gene mutations were detected in 79% of female 
never-smoker Asian patients. Targeted therapies for EGFR 
(erlotinib/gefitinib) and ALK (crizotinib) are currently 
available, and 70% of female never-smoker Asian patients 
with EGFR mutation (63%) or ALK rearrangement 
(7%) may benefit from such targeted therapies. An 
additional 10% of patients in our study may benefit from 
newly developed targeted drugs. A recent clinical trial 
described a partial response to the EGFR/HER2 inhibitor 
BIBW2922 in a HER2 mutant tumor [37], suggesting that 
this new drug is a promising treatment strategy. More 
comprehensive genomic analysis and deep sequencing 
may be necessary to identify genetic alterations in the 
remaining 20% of patients with no known mutations 
[26]. Notably, known driver gene mutations were found 
less frequently in mucinous adenocarcinoma in our study, 
suggesting the possibility of mutation in another driver 
gene in this histologic subtype.
In conclusion, lung cancer in never-smoker Asian 
females is a distinct entity, with the majority of these lung 
cancers developing from oncogenic mutations.
METHODS
Study population
Specimens were obtained from Samsung Medical 
Center (SMC) in Seoul, Korea with prior informed patient 
consent and approval by the Institutional Review Board 
of Samsung Medical Center. Between January 2008 
Oncotarget5472www.impactjournals.com/oncotarget
and January 2013, 3796 consecutive patients underwent 
pulmonary resection with curative intent for primary lung 
cancer at our institute.
After excluding 1307 patients with non-
adenocarcinoma (Figure 1A), the remaining 2489 patients 
consisted of 1302 men and 1187 women (Figure 1B). 
Of the 1187 female patients with lung adenocarcinoma, 
422 patients were excluded due to a lack of smoking 
information. Of the remaining 765 female patients, 94.9% 
(726 women) were never-smokers (Figure 1C). Among the 
726 never-smoker female pulmonary adenocarcinoma 
cases, 198 had sufficient tissue for genomic analysis and 
were included in this study.
Data collection and histologic classification of 
adenocarcinoma
Study data were abstracted from in-hospital charts 
and electronic medical records by trained experienced 
nurses from the Departments of Medical Oncology, Surgical 
Oncology, Laboratory Medicine, Pathology, and Nursing at 
Samsung Medical Center. Baseline clinical characteristics 
included gender, age at diagnosis, smoking history, alcohol 
consumption status, date of diagnosis of advanced lung 
cancer, tumor histology, tumor stage, and ambulatory status 
at diagnostic work-up. Tumor stage was defined according 
to the seventh edition of the American Joint Committee on 
Cancer [38]. Smoking history and alcohol consumption status 
were determined by self-reported answers on questionnaires. 
Never-smokers were defined as patients who smoked 
less than 100 cigarettes over their lifetime. Histologic 
classification was determined according to the International 
Association for the Study of Lung Cancer, American Thoracic 
Society, and European Respiratory Society classification 
of lung adenocarcinomas [39]. All histologic patterns that 
covered at least 10% of the tumor area were recorded, and the 
predominant pattern was defined as the pattern that covered 
the largest portion of the tumor area.
DNA and RNA extraction
Genomic DNA or RNA was extracted from lung 
tumors or distant histologically normal lung tissue using 
standard protocols (RNeasy Mini Kit and QIAamp DNA 
Mini Kit, Qiagen, Valencia, CA, USA).
ALK, ROS1, and RET fusion assays
The nCounter™ gene expression assays were custom-
designed and synthesized by NanoString Technologies 
(Seattle, WA, USA). Hybridization, sample cleanup, and 
digital reporter counts were performed according to the 
manufacturer’s protocol. RNA was obtained from fresh-
frozen tissues using the Qiagen RNeasy Mini Kit (Qiagen, 
Valencia, CA, USA). RNA concentration was assessed by 
spectrophotometry using the Nanodrop 8000 (Thermo-
Scientific, Wilmington, DE, USA).
Samples were processed according to the gene 
expression protocol of NanoString Technologies. Briefly, 
total RNA was hybridized to a multiplexed mixture of 
custom-designed nCounter™ capture and reporter probes 
complementary to ALK, ROS1, and RET target sequences 
(Supplemental Table 2) for at least 16 h at 65°C. The 
samples were cleaned up and processed using an 
automated nCounter™ Sample Prep Station (NanoString 
Technologies). Unhybridized probes were removed, 
and the hybridization complex was immobilized onto a 
cartridge and aligned. Fluorescently labeled, color-coded 
reporters were subsequently imaged on an nCounter™ 
Digital Analyzer (NanoString Technologies) set at 1155 
fields of view. Raw reporter counts were collected using 
nSolver software v1.0 (NanoString Technologies).
LungCarta analysis
High-throughput multiplex mutation profiling was 
performed using the MassARRAY® LungCarta Panel 
Version 1.0 (Sequenom, San Diego, CA, USA). This panel 
permits screening of 214 mutations across 26 oncogenes 
and tumor suppressors with a limit of sensitivity of 
approximately 10% with the use of 480 ng DNA [17]. 
DNA was amplified using the OncoCarta PCR primer 
mix, unincorporated nucleotides were inactivated by 
shrimp alkaline phosphatase, and a single base extension 
reaction was performed using extension primers that 
hybridize adjacent to the mutation. Multiplexed reactions 
were spotted onto the SpectroChipII (Sequenom) using 
the MassARRAY Nanodispenser. Peaks with different 
mass were resolved by matrix-assisted laser desorption/
ionization time-of-flight on the MassARRAY Compact 
Analyzer. A predefined ratio of expected normal allele 
to mutant allele at a specific nucleotide position allows 
mutations to be detected using primer extensions at 
that specific position. Because of the multiplexing 
capabilities of this assay, multiple mutations are detected 
simultaneously using one panel. Further details of the 
multiplex methodology can be found in the protocol 
provided by the manufacturer.
Sanger sequencing
To validate the LungCarta analysis, we performed 
Sanger sequencing of EGFR in 11 selected cases (4 cases 
of EGFR E746_A750del, 4 cases of EGFR L858R, and 3 
cases of KRAS G12D) according to the method described 
previously by our group [40].
Statistical analysis
Pearson’s chi-squared, Fisher’s exact, and 
independent t tests were used as indicated. All tests 
were two sided, and a p-value of < 0.05 was considered 
statistically significant. Statistical analyses were performed 
using SPSS software (SPSS Inc., Chicago, IL, USA).
Oncotarget5473www.impactjournals.com/oncotarget
ACkNOWLEDgMENTS
This study was supported by the Converging 
Research Center Program (No. 2013K000278) funded 
by the Korean government (The Ministry of Science, 
Information and Communications Technology, and Future 
Planning) and by the R&D Program for the Society of 
the National Research Foundation (NRF) funded by the 
Ministry of Science, ICT, and Future Planning (NRF-
2013M3C8A1078501) and by a grant of the Korea 
Health Technology R&D Project through the Korea Health 
Industry Development Institute(KHIDI), funded by the 
Ministry of Health & Welfare, Republic of Korea (grant 
number:HI13C2096).
REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 
Global cancer statistics. CA Cancer J Clin. 2011; 61:69–90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, 
Parkin DM. Estimates of worldwide burden of cancer in 
2008: GLOBOCAN 2008. International journal of cancer 
Journal international du cancer. 2010; 127:2893–2917.
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, the 
impact of eliminating socioeconomic and racial disparities on 
premature cancer deaths. CA Cancer J Clin. 2011; 61:212–236.
4. Scagliotti GV, Longo M, Novello S. Nonsmall cell lung 
cancer in never smokers. Current opinion in oncology. 
2009; 21:99–104.
5. Toh CK, Wong EH, Lim WT, Leong SS, Fong KW, Wee J, 
Tan EH. The impact of smoking status on the behavior 
and survival outcome of patients with advanced non-small 
cell lung cancer: a retrospective analysis. Chest. 2004; 
126:1750–1756.
6. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, 
Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, 
Pemberton K, Archer V, Carroll K. Gefitinib plus best 
supportive care in previously treated patients with refrac-
tory advanced non-small-cell lung cancer: results from a 
randomised, placebo-controlled, multicentre study (Iressa 
Survival Evaluation in Lung Cancer). Lancet. 2005; 
366:1527–1537.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, 
Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose 
Y, Nishiwaki Y, Ohe Y, Yang JJ, et al. Gefitinib or carbo-
platin-paclitaxel in pulmonary adenocarcinoma. The New 
England journal of medicine. 2009; 361:947–957.
8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, 
Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, 
Kinoshita I, Fujita Y, Okinaga S, Hirano H, et al. Gefitinib 
or chemotherapy for non-small-cell lung cancer with 
mutated EGFR. The New England journal of medicine. 
2010; 362:2380–2388.
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, 
Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, 
Hatanaka H, Bando M, Ohno S, Ishikawa Y, et al. 
Identification of the transforming EML4-ALK fusion gene 
in non-small-cell lung cancer. Nature. 2007; 448:561–566.
10. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, 
Menju T, Nakayama E, Mino N, Iwakiri S, 
Sato K, Miyahara R, Okubo K, Manabe T, Date H. 
Clinicopathologic features of non-small-cell lung cancer 
with EML4-ALK fusion gene. Annals of surgical oncology. 
2010; 17:889–897.
11. Solomon B, Varella-Garcia M, Camidge DR. ALK gene 
rearrangements: a new therapeutic target in a molecularly 
defined subset of non-small cell lung cancer. Journal of 
thoracic oncology: official publication of the International 
Association for the Study of Lung Cancer. 2009; 
4:1450–1454.
12. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, 
Xu C, Wang Y, Adelmant GO, Capelletti M, Lee HJ, 
Rodig SJ, Borgman C, et al. Inhibition of ALK, PI3K/
MEK, and HSP90 in murine lung adenocarcinoma induced 
by EML4-ALK fusion oncogene. Cancer research. 2010; 
70:9827–9836.
13. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, 
Lin J, Chen S, Xie Z, Zhu M, Wu YL. Fusion of EML4 and 
ALK is associated with development of lung adenocarcino-
mas lacking EGFR and KRAS mutations and is correlated 
with ALK expression. Mol Cancer. 2010; 9:188.
14. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, 
Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, 
McDermott U, Settleman J, Kobayashi S, Mark EJ, et al. 
Clinical features and outcome of patients with non-small-
cell lung cancer who harbor EML4-ALK. Journal of clini-
cal oncology: official journal of the American Society of 
Clinical Oncology. 2009; 27:4247–4253.
15. Ou SH, Ziogas A, Zell JA. Asian ethnicity is a favorable 
prognostic factor for overall survival in non-small cell lung 
cancer (NSCLC) and is independent of smoking status. J 
Thorac Oncol. 2009; 4:1083–1093.
16. Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, 
Park K, Ou SH. Korean ethnicity as compared with white 
ethnicity is an independent favorable prognostic factor for 
overall survival in non-small cell lung cancer before and 
after the oral epidermal growth factor receptor tyrosine 
kinase inhibitor era. J Thorac Oncol. 2010; 5:1185–1196.
17. Kawaguchi T, Matsumura A, Fukai S, Tamura A, Saito R, 
Zell JA, Maruyama Y, Ziogas A, Kawahara M, Ignatius 
Ou SH. Japanese ethnicity compared with Caucasian  ethnicity 
and never-smoking status are independent favorable prognos-
tic factors for overall survival in non-small cell lung cancer: 
a collaborative epidemiologic study of the National Hospital 
Organization Study Group for Lung Cancer (NHSGLC) in 
Japan and a Southern California Regional Cancer Registry 
databases. J Thorac Oncol. 2010; 5:1001–1010.
Oncotarget5474www.impactjournals.com/oncotarget
18. El-Telbany A, Ma PC. Cancer genes in lung cancer: racial 
disparities: are there any? Genes Cancer. 2012; 3:467–480.
19. Dearden S, Stevens J, Wu YL, Blowers D. Mutation inci-
dence and coincidence in non small-cell lung cancer: meta-
analyses by ethnicity and histology (mutMap). Ann Oncol. 
2013; 24:2371–2376.
20. Sun S, Schiller JH, Gazdar AF. Lung cancer in never 
 smokers–a different disease. Nat Rev Cancer. 2007; 
7:778–790.
21. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, 
Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, 
Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, et al. 
Using multiplexed assays of oncogenic drivers in lung can-
cers to select targeted drugs. JAMA. 2014; 311:1998–2006.
22. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, 
Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh  S, 
Rischin D, Eek R, Horai T, Noda K, et al. Multi-institutional 
randomized phase II trial of gefitinib for previously treated 
patients with advanced non-small-cell lung cancer (The 
IDEAL 1 Trial). J Clin Oncol. 2003; 21:2237–2246.
23. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, 
Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, 
Venkatraman E, Ben-Porat L, et al. Bronchioloalveolar 
pathologic subtype and smoking history predict sensitivity 
to gefitinib in advanced non-small-cell lung cancer. J Clin 
Oncol. 2004; 22:1103–1109.
24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, 
Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, 
Asami K, Katakami N, Takada M, et al. Gefitinib versus 
cisplatin plus docetaxel in patients with non-small-cell lung 
cancer harbouring mutations of the epidermal growth factor 
receptor (WJTOG3405): an open label, randomised phase 3 
trial. Lancet Oncol. 2010; 11:121–128.
25. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, 
Wang R, Hu H, Li H, Wang L, Pao W, et al. Frequency 
of driver mutations in lung adenocarcinoma from female 
never-smokers varies with histologic subtypes and age at 
diagnosis. Clin Cancer Res. 2012; 18:1947–1953.
26. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, 
Pao W, Chen H, Ji H. Lung adenocarcinoma from East Asian 
never-smokers is a disease largely defined by targetable onco-
genic mutant kinases. J Clin Oncol. 2010; 28:4616–4620.
27. Ren S, Chen X, Kuang P, Zheng L, Su C, Li J, Li B, 
Wang Y, Liu L, Hu Q, Zhang J, Tang L, Li X, et al. 
Association of EGFR mutation or ALK rearrangement with 
expression of DNA repair and synthesis genes in never-
smoker women with pulmonary adenocarcinoma. Cancer. 
2012; 118:5588–5594.
28. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, 
Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, 
Iwakawa R, Ogiwara H, Oike T, et al. KIF5B-RET fusions 
in lung adenocarcinoma. Nat Med. 2012; 18:375–377.
29. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim 
YT, Kim JI, Kang JH, Seo JS. A transforming KIF5B and 
RET gene fusion in lung adenocarcinoma revealed from 
whole-genome and transcriptome sequencing. Genome Res. 
2012; 22:436–445.
30. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, 
McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, 
Fang R, Mark EJ, Batten JM, Chen H, et al. ROS1 rear-
rangements define a unique molecular class of lung cancers. 
J Clin Oncol. 2012; 30:863–870.
31. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky  R, 
Temel JS, Lennes IT, Digumarthy S, Waltman BA, 
Bast E, Tammireddy S, Morrissey L, Muzikansky A, 
et al. Implementing multiplexed genotyping of non- 
small-cell lung cancers into routine clinical practice. Ann 
Oncol. 2011; 22:2616–2624.
32. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, 
Koh JS, Baek HJ, Lee JC, Na II. Association between age 
at diagnosis and the presence of EGFR mutations in female 
patients with resected non-small cell lung cancer. J Thorac 
Oncol. 2010; 5:1949–1952.
33. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu 
XY, Pao W, Chen H, Ji H. Spectrum of oncogenic driver 
mutations in lung adenocarcinomas from East Asian never 
smokers. PLoS One. 2011; 6:e28204.
34. Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, 
Han J, Park K, Ahn MJ, Kim J. Clinical characteristics 
associated with ALK rearrangements in never-smokers 
with pulmonary adenocarcinoma. Lung Cancer. 2014; 
83:259–264.
35. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, 
Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, 
Lynch T, Johnson BE, et al. Unique clinicopathologic features 
characterize ALK-rearranged lung adenocarcinoma in the 
western population. Clin Cancer Res. 2009; 15:5216–5223.
36. Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. 
KRAS mutations are associated with solid growth pattern 
and tumor-infiltrating leukocytes in lung adenocarcinoma. 
Mod Pathol. 2013; 26:1307–1319.
37. De Greve J, Teugels E, Geers C, Decoster L, Galdermans 
D, De Mey J, Everaert H, Umelo I, In’t Veld P, Schallier D. 
Clinical activity of afatinib (BIBW 2992) in patients with 
lung adenocarcinoma with mutations in the kinase domain 
of HER2/neu. Lung Cancer. 2012; 76:123–127.
38. Tanoue LT, Detterbeck FC. New TNM classification for 
non-small-cell lung cancer. Expert Rev Anticancer Ther. 
2009; 9:413–423.
39. Travis WD, Brambilla E, Noguchi M, Nicholson AG, 
Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, 
Van Schil PE, Garg K, Austin JH, Asamura H, et al. 
International association for the study of lung cancer/
american thoracic society/european respiratory society 
international multidisciplinary classification of lung ade-
nocarcinoma. J Thorac Oncol. 2011; 6:244–285.
40. Ha SY, Han J, Lee JJ, Kim YE, Choi Y-L, Kim HK. 
Mucoepidermoid Carcinoma of Tracheobronchial Tree: 
Clinicopathological Study of 31 Cases. The Korean Journal 
of Pathology. 2011; 45:175–181.
